Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
Saved in:
| Title: | Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction. |
|---|---|
| Authors: | Conroy S; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Gagg H; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Quayle LA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; School of Computing and Digital Technologies, Sheffield Hallam University, Sheffield, UK., Adams JA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Williams ST; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Helleday T; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden., Hussain SA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Griffin J; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Allen R; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Rantala JK; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Misvik Biology Ltd, Karjakatu, Turku, Finland., Danson SJ; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. s.danson@sheffield.ac.uk.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. s.danson@sheffield.ac.uk., Catto J; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. j.catto@sheffield.ac.uk.; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. j.catto@sheffield.ac.uk., Wells G; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. g.wells@sheffield.ac.uk. |
| Source: | Communications medicine [Commun Med (Lond)] 2026 May 14. Date of Electronic Publication: 2026 May 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
